We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (BOS2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01508000
Recruitment Status : Terminated (Low or poor accrual)
First Posted : January 11, 2012
Last Update Posted : October 12, 2016
Roche Pharma AG
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Primary Completion Date : September 2016
  Study Completion Date : September 2016